Search research articles
Contact Us
Filters
Showing results (121-130 of 152) with videos related to
Page
of 16
Sort By:
Plos One
|
March 11, 2016
Inter-Reader Reliability of Early FDG-PET/CT Response Assessment Using the Deauville Scale after 2 Cycles of Intensive Chemotherapy (OEPA) in Hodgkin's Lymphoma
Regine Kluge, Lidia Chavdarova, Martha Hoffmann, et al.
Hemasphere
|
August 20, 2025
Brentuximab vedotin, cyclophosphamide, doxorubicin, and prednisone for advanced-stage Hodgkin lymphoma in older patients
Paul J Bröckelmann, Boris Böll, Daniel Molin, et al.
Blood
|
April 2, 2026
Gonadal Function and Fertility after Hodgkin Lymphoma Treatment with Nivolumab-AVD in the Phase II GHSG NIVAHL Trial
Anne Sophie Robertz, Ina Bühnen, Julia Meissner, et al.
Hemasphere
|
June 25, 2026
Hodgkin lymphoma: EHA Clinical Practice Guidelines for diagnosis, treatment, and follow-up
Dennis A Eichenauer, Marc André, Peter Borchmann, et al.
Strahlentherapie Und Onkologie : Organ Der Deutschen Rontgengesellschaft ... [Et Al]
|
August 9, 2024
Implementation of PET/CT in radiation oncology-a patterns-of-care analysis of the German Society of Nuclear Medicine and the German Society of Radiation Oncology
Simone Wegen, Ursula Nestle, Constantinos Zamboglou, et al.
British Journal of Haematology
|
November 14, 2021
Reinduction therapy with everolimus in combination with dexamethasone, high-dose cytarabin and cisplatinum in patients with relapsed or refractory classical Hodgkin lymphoma: an experimental phase I/II multicentre trial of the German Hodgkin Study Group (GHSG HD-R3i)
Sarah Gillessen, Andreas Hüttmann, Vladan Vucinic, et al.
The Lancet. Oncology
|
February 26, 2017
Progression-free survival of early interim PET-positive patients with advanced stage Hodgkin's lymphoma treated with BEACOPP<sub>escalated</sub> alone or in combination with rituximab (HD18): an open-label, international, randomised phase 3 study by the German Hodgkin Study Group
Peter Borchmann, Heinz Haverkamp, Andreas Lohri, et al.
Hemasphere
|
January 26, 2023
Outcome Prediction in Patients With Large B-cell Lymphoma Undergoing Chimeric Antigen Receptor T-cell Therapy
Conrad-Amadeus Voltin, Philipp Gödel, Laura Beckmann, et al.
British Journal of Haematology
|
August 28, 2015
Impact of centralized diagnostic review on quality of initial staging in Hodgkin lymphoma: experience of the German Hodgkin Study Group
Paul J Bröckelmann, Helen Goergen, Michael Fuchs, et al.
JAMA Oncology
|
May 1, 2020
Efficacy of Nivolumab and AVD in Early-Stage Unfavorable Classic Hodgkin Lymphoma: The Randomized Phase 2 German Hodgkin Study Group NIVAHL Trial
Paul J Bröckelmann, Helen Goergen, Ulrich Keller, et al.
Page
of 16
Search research articles
Search
Showing results (121-130 of 152) with videos related to
Sort By:
Page
of 16
Plos One
|
March 11, 2016
Inter-Reader Reliability of Early FDG-PET/CT Response Assessment Using the Deauville Scale after 2 Cycles of Intensive Chemotherapy (OEPA) in Hodgkin's Lymphoma
Regine Kluge, Lidia Chavdarova, Martha Hoffmann, et al.
Hemasphere
|
August 20, 2025
Brentuximab vedotin, cyclophosphamide, doxorubicin, and prednisone for advanced-stage Hodgkin lymphoma in older patients
Paul J Bröckelmann, Boris Böll, Daniel Molin, et al.
Blood
|
April 2, 2026
Gonadal Function and Fertility after Hodgkin Lymphoma Treatment with Nivolumab-AVD in the Phase II GHSG NIVAHL Trial
Anne Sophie Robertz, Ina Bühnen, Julia Meissner, et al.
Hemasphere
|
June 25, 2026
Hodgkin lymphoma: EHA Clinical Practice Guidelines for diagnosis, treatment, and follow-up
Dennis A Eichenauer, Marc André, Peter Borchmann, et al.
Strahlentherapie Und Onkologie : Organ Der Deutschen Rontgengesellschaft ... [Et Al]
|
August 9, 2024
Implementation of PET/CT in radiation oncology-a patterns-of-care analysis of the German Society of Nuclear Medicine and the German Society of Radiation Oncology
Simone Wegen, Ursula Nestle, Constantinos Zamboglou, et al.
British Journal of Haematology
|
November 14, 2021
Reinduction therapy with everolimus in combination with dexamethasone, high-dose cytarabin and cisplatinum in patients with relapsed or refractory classical Hodgkin lymphoma: an experimental phase I/II multicentre trial of the German Hodgkin Study Group (GHSG HD-R3i)
Sarah Gillessen, Andreas Hüttmann, Vladan Vucinic, et al.
The Lancet. Oncology
|
February 26, 2017
Progression-free survival of early interim PET-positive patients with advanced stage Hodgkin's lymphoma treated with BEACOPP<sub>escalated</sub> alone or in combination with rituximab (HD18): an open-label, international, randomised phase 3 study by the German Hodgkin Study Group
Peter Borchmann, Heinz Haverkamp, Andreas Lohri, et al.
Hemasphere
|
January 26, 2023
Outcome Prediction in Patients With Large B-cell Lymphoma Undergoing Chimeric Antigen Receptor T-cell Therapy
Conrad-Amadeus Voltin, Philipp Gödel, Laura Beckmann, et al.
British Journal of Haematology
|
August 28, 2015
Impact of centralized diagnostic review on quality of initial staging in Hodgkin lymphoma: experience of the German Hodgkin Study Group
Paul J Bröckelmann, Helen Goergen, Michael Fuchs, et al.
JAMA Oncology
|
May 1, 2020
Efficacy of Nivolumab and AVD in Early-Stage Unfavorable Classic Hodgkin Lymphoma: The Randomized Phase 2 German Hodgkin Study Group NIVAHL Trial
Paul J Bröckelmann, Helen Goergen, Ulrich Keller, et al.
Page
of 16